Xenon Gas Revealed As Potential Alzheimer’s Disease Treatment, Leading To Clinical Trial

Alzheimer’s disease (AD), the most prevalent neurodegenerative disorder, continues to pose significant challenges despite advances in anti-amyloid therapies. New research from Harvard Medical School and Washington University School of Medicine, published in Science Translational Medicine, has unveiled a novel therapeutic approach: the use of inhaled xenon gas to modulate microglia and ameliorate disease progression in mouse models of AD.

How Xenon Targets Microglia

Microglia, the brain’s resident immune cells, play a dual role in neurodegeneration. While they can clear amyloid-beta (Aβ) plaques and damaged neurons, chronic activation leads to neuroinflammation, contributing to disease progression. Xenon gas, an inert anaesthetic, penetrates the blood-brain barrier and appears to modulate microglia to adopt a “pre-neurodegenerative microglia” (pre-MGnD) state.

Dr. Oleg Butovsky, a senior author of the study, explains, “Xenon inhalation induces microglial activation that enhances amyloid plaque compaction and suppresses neuroinflammation. This therapeutic modulation holds promise for addressing key pathological features of Alzheimer’s.”

Key Findings from the Study

1. Amyloidosis and Tauopathy Models:

Xenon inhalation improved outcomes in two major mouse models of AD—amyloidosis (APP/PS1 and 5xFAD) and tauopathy (P301S). It reduced amyloid plaque burden, diminished dystrophic neurites, and mitigated brain atrophy.

2. Microglial Function:

Xenon-treated mice showed enhanced microglial phagocytosis, with upregulated genes supporting lysosomal function and anti-inflammatory pathways, while downregulating pro-inflammatory genes such as IL1A and TNF.

3. Behavioural Improvements:

Behavioural tests revealed that xenon inhalation rescued nest-building deficits in mouse models, a surrogate for cognitive and motor function in AD.

4. Mechanistic Insights:

The study identified interferon-gamma (IFN-γ) signalling as a key driver of the microglial shift, promoting a homeostatic phenotype while suppressing inflammatory markers.

Preliminary Clinical Trial Results

In addition to preclinical findings, the study included a pilot clinical trial involving participants with mild cognitive impairment (MCI) or mild Alzheimer’s disease. The trial demonstrated that xenon inhalation was well-tolerated, with no significant adverse effects reported. Early data suggested that xenon modulated microglial activity and influenced biomarkers associated with AD pathology. While these findings are promising, larger-scale clinical trials are necessary to confirm the therapeutic potential of xenon gas in human patients.

Broader Implications for Alzheimer’s Therapy

This research underscores the potential of xenon gas as a non-invasive treatment for AD. Unlike current therapies targeting amyloid directly, xenon acts on the brain’s immune system, reshaping microglial activity to slow neurodegeneration. The study also highlights the broader role of microglia in neurodegenerative diseases, suggesting that similar approaches could benefit other conditions like Parkinson’s or frontotemporal dementia.

The Path to Translation

Using xenon gas, already employed in clinical anaesthesia, could streamline its path to approval for neurological applications. With further research and more extensive trials, xenon inhalation may emerge as a transformative therapy in the fight against Alzheimer’s.

Original Article: Brandao, W., Jain, N., Yin, Z., Kleemann, K. L., Carpenter, M., Bao, X., Serrano, J. R., Tycksen, E., Durao, A., Barry, J.-L., Baufeld, C., Guneykaya, D., Zhang, X., Litvinchuk, A., Jiang, H., Rosenzweig, N., Pitts, K. M., Aronchik, M., Yahya, T., … Butovsky, O. (2025). Inhaled xenon modulates microglia and ameliorates disease in mouse models of amyloidosis and tauopathy. Science Translational Medicine, 17(781), eadk3690. https://doi.org/10.1126/scitranslmed.adk3690